{"date":"2025-09-07","count":2,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6677-2025-09-07-2200-q0ccdp","company_id":"6677","company":"瑩碩生技","market":"興櫃","industry":"生技醫療","date":"2025-09-07","time":"22:00:09","subject":"公告本公司治療思覺失調症505(b)(2)新藥AX251，向美國食品藥物管理局(FDA)提出人體臨床試驗審查申請(IND)","clause":"第44款","fact_date":"2025-09-06","cite_as":"公開資訊觀測站重大訊息：瑩碩生技（6677），2025-09-07 22:00，「公告本公司治療思覺失調症505(b)(2)新藥AX251，向美國食品藥物管理局(FDA)提出人體臨床試驗審查申請(IND」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6589-2025-09-07-1931-ymujqe","company_id":"6589","company":"台康生技","market":"上市","industry":"生技醫療","date":"2025-09-07","time":"19:31:56","subject":"本公司授權夥伴Sandoz獲得歐洲藥品局(EMA)同意生物相似藥品Herwenda-Trastuzumab EG12014 (150 mg)之上市後變更","clause":"第51款","fact_date":"2025-09-05","cite_as":"公開資訊觀測站重大訊息：台康生技（6589），2025-09-07 19:31，「本公司授權夥伴Sandoz獲得歐洲藥品局(EMA)同意生物相似藥品Herwenda-Trastuzumab EG1201」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}